Platelet-rich fibrin and its use in dentistry

Year 2022, Volume: 3 Issue: 4, 386 - 393, 26.12.2022

Sarah Khaled , Ebru Olgun , Meltem Hendek

https://doi.org/10.47582/jompac.1212693

Abstract

PRF is often defined as an autogenous fibrin biomaterial rich in leukocytes and platelets and is clinically easy to obtain and use. Various methods are available to prepare platelet concentrates, albeit the contents of platelet concentrates obtained by different methods also vary. Accordingly, they are divided into P-PRF, L-PRF, i-PRF, A-PRF, and A-PRF+, considering the thrombocyte leukocyte concentrates and fibrin contents. PRF is widely adopted in dentistry as promoting angiogenesis, immunity, and epithelial proliferation.

Keywords

PRF, P-PRF, L-PRF, i-PRF, A-PRF, A-PRF+

Trombositten zengin fibrin ve diş hekimliğinde kullanımı

Abstract

TZF, lökositten ve trombositten zengin otojen bir fibrin biyomateryali olarak tanımlanmıştır . TZF’nin elde eldilmesi ve klinik kullanımı kolaydır. Trombosit konsantrelerinin hazırlanmasında değişik yöntemler mevcuttur. Farklı yöntemlerle elde edilen trombosit konsantrelerinin içeriği de farklıdır. Buna göre trombosit lökosit konsantrelerinin ve fibrin içerikleri göz önünde bulundurularak S-TZF, L-TZF, E-TZF, G-TZF ve G-TZF+ olarak gruplara ayrılmaktadır. TZF, anjiojenez, bağışıklık ve epitel proliferasyonu desteklediği için diş hekimliğinde yaygın bir şekilde kullanılmaktadır.

Keywords

TZF, S-TZF, L-TZF, E-TZF, G-TZF, G-TZF+

References

• Anitua E, Sanchez M, Orive G, Andia I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials 2007; 28: 4551-60.
• Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofacial Implants 1999; 14: 529-35.
• Badiavas EV, Abedi M, Butmarc J, Falanga V, Quesenberry P. Participation of bone marrow derived cells in cutaneous wound healing. J Cellular Physiology 2003; 196: 245-50.
• Bensaıd W, Triffitt JT, Blanchat C, Oudina K, Sedel L, Petite H. A biodegradable fibrin scaffold for mesenchymal stem cell transplantation. Biomaterials 2003; 24: 2497-502.
• Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286-92.
• Choukroun J, Adda F, Schoeffler C, Vervelle AP. Une opportunité en paro-implantologie: le PRF. Implantodontie 2001; 42: 55-62.
• Choukroun J, Diss A, Simonpieri A, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part IV: Clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2006, 101: e56-60.
• Choukroun JI, Braccini F, Diss A, Giordano G, Doglioli P, Dohan DM. Influence of platelet rich fibrin (PRF) on proliferation of human preadipocytes and tympanic keratinocytes: A new opportunity in facial lipostructure (Coleman’s technique) and tympanoplasty? Revue de Laryngologie-Otologie-Rhinologie 2007; 128: 27-32.
• Del Corso M, Toffler M, Dohan Ehrenfest DM. Use of an autologous leukocyte and platelet-rich fibrin (L-PRF) membrane in post-avulsion sites: an overview of Choukroun’s PRF. J Implant Adv Clin Dent 2010; 1: 27-35.
• Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2006; 101: e37-44.
• Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2006; 101: e45-50.
• Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: A new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2006; 101: e51-5.
• Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun’s platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors 2009; 27: 63-9.
• Dohan Ehrenfest DM, Del Corso M, Diss A, Mouhyi J, Charrier JB. Three‐dimensional architecture and cell composition of a Choukroun’s platelet‐rich fibrin clot and membrane. J Periodontol 2010; 81: 546-55.
• Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF). Trends in Biotechnology 2009; 27: 158-67.
• El Bagdadi K, Kubesch A, Yu X, et al. Reduction of relative centrifugal forces increases growth factor release within solid platelet-rich-fibrin (PRF)-based matrices: a proof of concept of LSCC (low speed centrifugation concept). Eur J Trauma Emerg Surg 2019; 45: 467-79.
• El‐Sharkawy H, Kantarci A, Deady J, et al. Platelet‐rich plasma: growth factors and pro‐and anti‐inflammatory properties. J Periodontol 2007; 78: 661-9.
• Ercan E, Suner SS, Silan C, et al. Titanium platelet–rich fibrin (T-PRF) as high-capacity doxycycline delivery system. Clin Oral Invest 2022; 26; 5429-38.
• Everts PA, van Zundert A, Schonberger JP, Devilee RJ, Knape JT. What do we use: platelet-rich plasma or platelet-leukocyte gel? J Biomedical Materials Research Part A 2008; 85: 1135-6.
• Feng X, Clark RA, Galanakis D, Tonnesen MG. Fibrin and collagen differentially regulate human dermal microvascular endothelial cell integrins: stabilization of αv/β3 mRNA by fibrin. J Investigative Dermatol 1999; 113: 913-9.
• Ghanaati S, Booms P, Orlowska A, et al. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. J Oral Implantology 2014;40: 679-89.
• Harry LE, Paleolog EM. From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. Birth Defects Research Part C: Embryo Today: Reviews 2003; 69: 363-74.
• Hayashi Y, Kobayashi M, Kuwata H, et al. Interferon-γ and interleukin 4 inhibit interleukin 1β-induced delayed prostaglandin E2generation through suppression of cyclooxygenase-2 expression in human fibroblasts. Cytokine 2000; 12: 603-12.
• Karde PA, Sethi KS, Mahale SA, Khedkar SU, Patil AG, Joshi CP. Comparative evaluation of platelet count and antimicrobial efficacy of injectable platelet-rich fibrin with other platelet concentrates: an in vitro study. J Indian Soc Periodontol 2017; 21: 97-101.
• Koçyiğit İ, Tunalı M, Özdemir H, Kartal Y, Süer B. İkinci nesil trombosit konsantrasyonunun klinik uygulamalari. Cumhuriyet Dental J 2012; 15: 279-87.
• Kour P, Pudakalkatti PS, Vas AM, Das S, Padmanabhan S. Comparative evaluation of antimicrobial efficacy of platelet-rich plasma, platelet-rich fibrin, and injectable platelet-rich fibrin on the standard strains of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans. Contemporary Clin Dent 2017; 8: 538-44.
• Lee EH, Kim JY, Kweon HY, et al. A combination graft of low-molecular-weight silk fibroin with Choukroun platelet-rich fibrin for rabbit calvarial defect. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2010; 109: e33-8.
• Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 1998; 85: 638-46.
• Olgun E, Ozkan SY, Atmaca HT, Yalim M, Hendek MK. Comparison of the clinical, radiographic, and histological effects of titanium‐prepared platelet rich fibrin to allograft materials in sinus‐lifting procedures. J Investigative Clin Dent 2018; 9: e12347.
• Saglam E, Ozsagir ZB, Unver T, Alinca SB, Toprak A, Tunali M. Efficacy of injectable platelet-rich fibrin in the erosive oral lichen planus: A split-mouth, randomized, controlled clinical trial. J Applied Oral Sci 2021; 29: 1590-678.
• Simonpieri A, Del Corso M, Sammartino G, Ehrenfest DM. The relevance of Choukroun’s platelet-rich fibrin and metronidazole during complex maxillary rehabilitations using bone allograft. Part I: A new grafting protocol. Implant Dentistry 2009; 18: 102-11.
• Tunalı M, Özdemir H, Küçükodacı Z, Akman S, Fıratlı E. In vivo evaluation of titanium-prepared platelet-rich fibrin (T-PRF): A new platelet concentrate. British J Oral Maxillofac Surg 2013; 51: 438-43.
• Tunali M, Ozdemir H, Pikdoken L, Gurbuzer B, Selcuk OR. Endodontik-periodontal kombine kemik içi defektlerin tedavisinde trombositten zengin fibrin membran ile otojen kemik greftinin kombine kullanımı: olgu sunumu. Cumhuriyet Dent J 2011; 12: 43-6.
• Varshney S, Dwivedi A, Pandey V. Antimicrobial effects of various platelet rich concentrates-vibes from in-vitro studies-a systematic review. J Oral Biol Craniofac Res 2019; 9: 299-305.
• Yu JH, Ustach C, ChoiKim HR. Platelet-derived growth factor signaling and human cancer. BMB Reports 2003; 36: 49-59.
• Johns, D. A, Shivashankar, V. Y, Krishnamma, S, & Johns, M.Use of photoactivated disinfection and platelet-rich fibrin in regenerative Endodontics. Journal of conservative dentistry 2014; 17: 487–90.
• Francisco I, Fernandes MH, Vale F. Platelet-rich fibrin in bone regenerative strategies in orthodontics: a systematic review. Materials (Basel, Switzerland) 2020; 13: 1866.
• Singh R, Singh R, Kavita K, Kommula A, Kulkarni G, Jois HS. To compare mineral trioxide aggregate, platelet-rich fibrin, and calcium hydroxide in teeth with irreversible pulpitis: a clinical study. J Pharm Bioallied Sci 2020: 436–9.
• Erdur EA, Karakaslı K, Oncu E, Ozturk B, Hakkı S. Effect of injectable platelet-rich fibrin (i-PRF) on the rate of tooth movement.  Angle Orthodont 2021; 91: 285–92.
• Masuki, H, Okudera, T, Watanebe, T, et al. Growth factor and pro-inflammatory cytokine contents in platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated growth factors (CGF). Int J Implant Dentistry 2016, 2: 19.